NCT05976997

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Liling Zhang · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.

Detailed description

This is a prospective, single arm, single center study, including two phases. It plans to recruit36 patients with clinically diagnosed primary PTCL who will be treated with Duvelisib and Chidamide. In the first phase Duvelisib is Oral administration at a dose of 25mg twice a day, and every 4 weeks (28 days) was a cycle. Next administration will be depend on whether the efficacy reaches CR in the second phase.

Conditions

• Newly Diagnosed Peripheral T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Duvelisib, Chidamide	Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;

Timeline

• Start date: 2023-05-08
• Primary completion: 2023-12-01
• Completion: 2024-12-01
• First posted: 2023-08-04
• Last updated: 2023-08-04

Locations

1 site across 1 country: China